ATE277607T1 - Aldose reductase hemmung zur vorbeugung oder zur umkehrung der diabetischen kardiomyopathie - Google Patents

Aldose reductase hemmung zur vorbeugung oder zur umkehrung der diabetischen kardiomyopathie

Info

Publication number
ATE277607T1
ATE277607T1 AT98303447T AT98303447T ATE277607T1 AT E277607 T1 ATE277607 T1 AT E277607T1 AT 98303447 T AT98303447 T AT 98303447T AT 98303447 T AT98303447 T AT 98303447T AT E277607 T1 ATE277607 T1 AT E277607T1
Authority
AT
Austria
Prior art keywords
prevent
aldose reductase
diabetic cardiomyopathy
reductase inhibition
reverse diabetic
Prior art date
Application number
AT98303447T
Other languages
English (en)
Inventor
Brian Frank Johnson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE277607T1 publication Critical patent/ATE277607T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98303447T 1997-05-05 1998-05-01 Aldose reductase hemmung zur vorbeugung oder zur umkehrung der diabetischen kardiomyopathie ATE277607T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4582297P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
ATE277607T1 true ATE277607T1 (de) 2004-10-15

Family

ID=21940071

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98303447T ATE277607T1 (de) 1997-05-05 1998-05-01 Aldose reductase hemmung zur vorbeugung oder zur umkehrung der diabetischen kardiomyopathie

Country Status (17)

Country Link
US (1) US5990111A (de)
EP (1) EP0880964B1 (de)
JP (1) JP3010153B2 (de)
KR (1) KR19980086748A (de)
AT (1) ATE277607T1 (de)
AU (1) AU725621B2 (de)
CA (1) CA2236553C (de)
DE (1) DE69826561T2 (de)
DK (1) DK0880964T3 (de)
ES (1) ES2227773T3 (de)
HU (1) HUP9801022A3 (de)
IL (1) IL124236A (de)
MY (1) MY136261A (de)
NZ (1) NZ330359A (de)
PT (1) PT880964E (de)
TW (1) TW589184B (de)
ZA (1) ZA983720B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US6413965B1 (en) * 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
CA2382228A1 (en) * 1999-08-23 2001-03-01 University Of Virginia Patent Foundation Method and apparatus for predicting the risk of hypoglycemia
US20020068740A1 (en) * 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US20050239063A1 (en) * 2001-03-30 2005-10-27 Lee Shao C Determination of risk factors for cataract by aldose reductase genotype
US20040047919A1 (en) * 2002-06-13 2004-03-11 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
US8273746B2 (en) * 2007-03-23 2012-09-25 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
WO2012088525A2 (en) 2010-12-23 2012-06-28 The Board Of Regents Of The University Of Texas System Methods for treating copd

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
ES2032749T3 (es) * 1985-11-07 1993-03-01 Pfizer Inc. Acidos oxoftalazinil-aceticos heterociclicos.
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
EP0322153A3 (de) * 1987-12-21 1990-08-16 Pfizer Inc. Heterozyklyl Oxophtalazynyl-Essigsäuren
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US5164391A (en) * 1989-09-20 1992-11-17 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes and circulatory diseases
WO1991009019A1 (en) * 1989-12-15 1991-06-27 Pfizer Inc. Substituted oxophthalazinyl acetic acids and analogs thereof
US5064830A (en) * 1990-08-02 1991-11-12 Pfizer Inc. Lowering of blood uric acid levels
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia

Also Published As

Publication number Publication date
TW589184B (en) 2004-06-01
CA2236553C (en) 2002-10-29
EP0880964B1 (de) 2004-09-29
DK0880964T3 (da) 2004-12-27
CA2236553A1 (en) 1998-11-05
DE69826561T2 (de) 2006-03-09
JP3010153B2 (ja) 2000-02-14
IL124236A (en) 2003-01-12
NZ330359A (en) 2000-06-23
DE69826561D1 (de) 2004-11-04
KR19980086748A (ko) 1998-12-05
PT880964E (pt) 2004-12-31
MY136261A (en) 2008-09-30
HUP9801022A3 (en) 2001-10-29
ES2227773T3 (es) 2005-04-01
EP0880964A2 (de) 1998-12-02
AU6380198A (en) 1998-11-05
JPH10316588A (ja) 1998-12-02
ZA983720B (en) 1999-11-04
US5990111A (en) 1999-11-23
EP0880964A3 (de) 2002-07-17
HUP9801022A2 (hu) 2000-03-28
AU725621B2 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE69826561D1 (de) Aldose Reductase Hemmung zur Vorbeugung oder zur Umkehrung der diabetischen Kardiomyopathie
NL300288I2 (nl) Behandeling van diabetes met thiazolidinedion en metformine.
HUP0202853A2 (hu) A retigabin alkalmazása neuropátiás fájdalom kezelésére
DE69733329D1 (de) Verwendung von Taurin zur Behandlung oder Vorbeugung von ischämischen Verletzungen
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
TR200200204T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
HK1077755A1 (en) Use of a paralpha agonist and metformin for the treatment of obesity ppar-alpha
DK1017408T3 (da) Anvendelse af tetrahydrolipstatin i behandling af diabetes type II
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DK0813870T3 (da) Anvendelse af darifenacin til at forstærke kognitive funktioner
DE60121771D1 (de) Verwendung von alginaten zur hemmung des pepsins
NO20012962L (no) Martensittisk rustfritt stål
DE50209171D1 (de) Verhinderung von membranverblockung bei der abwasseraufbereitung bei der phosphatierung
GB9626472D0 (en) New use of comt inhibitors
DE60033569D1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
DE59808165D1 (de) Verwendung von aminothiazolen zur wund- und hautbehandlung
ATE377586T1 (de) Tripeptidylpeptidaseinhibitoren
DE69901189T2 (de) Oberflächenbehandlung von stahl
DE29702143U1 (de) Strahlregler, oder Perlatorschlüssel
DK1490510T3 (da) Hidtil ukendte primere til at identificere aflatoksikogene Aspergilli og forbedret anvendelse deraf
PT1017377E (pt) Utilizacao de 2-aminotetralinas 6,7-substituidas para o tratamento de condicoes inflamatorias mediadas por citoquina
ES1037450Y (es) Ferula para el tratamiento de uñas incarnadas y restablecimiento de la curvatura de las mismas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0880964

Country of ref document: EP

REN Ceased due to non-payment of the annual fee